Ads
related to: dupixent commercial- Before & After Photos
See the Before and After of What
A Treatment Option Can Do For You.
- Psoriasis Symptoms
Learn More Information About
The Symptoms of Plaque Psoriasis.
- Side Effects
What You Need To Know
About Benefits and Side Effects
- Sign Up for Info
Get Updates, Answers, and Resources
For Treatment Support
- Dosage Information
Learn about Dosage Information
For How to Take Treatment
- Watch Videos
Watch A Video To Learn More
About A Treatment Option.
- Before & After Photos
Search results
Regeneron, Sanofi to seek new Dupixent approval in US after COPD success
BioPharma Dive via Yahoo Finance· 5 months agoResults from the second of two Phase 3 trials testing the blockbuster drug in the respiratory...
What This Drug News Could Mean for Sanofi Shareholders
Motley Fool· 1 year agoIn the middle of December, Sanofi's (NASDAQ: SNY) and Regeneron Pharmaceuticals' (NASDAQ: REGN)...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 16 hours agoRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2024 Earnings Call Transcript May 2, 2024 Regeneron...
Regeneron Pharmaceuticals Inc (REGN) Reports Modest Revenue Growth Amidst Strong Dupixent Sales
GuruFocus.com via Yahoo Finance· 3 months agoRevenue Growth: Full year 2023 revenues increased by 8% to $13.12 billion, with a 14% rise excluding...
Sanofi Expects Moderate 2023 Profit Growth On Dupixent Demand, But Dampened By Aubagio Generics...
Benzinga via Yahoo Finance· 1 year agoSanofi SA (NASDAQ: SNY) forecasts 2023 adjusted earnings per share to grow by a "low single-digit"...
Sanofi (SNY) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 1 week agoImage source: The Motley Fool. Sanofi (NASDAQ: SNY) Q1 2024 Earnings Call Apr 25, 2024, 8:30 a.m. ET Contents: Prepared Remarks Questions and Answers...
Regeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings Call Transcript Highlights: Key Financial ...
GuruFocus.com via Yahoo Finance· 23 hours agoRevenue: Grew 7% year-over-year to $3.1 billion, excluding COVID antibodies contributions. Net Income: First quarter diluted net income per share was $9.55. Free Cash Flow: Generated $1.4 billion ...
Regeneron Pharmaceuticals Inc (REGN) Reports 15% Revenue Growth in Q3 2023
GuruFocus.com via Yahoo Finance· 6 months agoRegeneron Pharmaceuticals Inc (NASDAQ:REGN) reported a 15% increase in revenues to $3.36 billion in...
Sanofi trial failure halts work on breast cancer treatment amcenestrant
Reuters via Yahoo News· 2 years agoSanofi has stopped further work on amcenestrant, a treatment once seen to have strong commercial...
Analysis-Meagre medicine cabinet leaves Sanofi unloved
Reuters via Yahoo News· 2 years agoSanofi's recent stock rout underscores the pressure on the French drug maker to redouble its efforts...
Ad
related to: dupixent commercial
